FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicCNBC: US News • 2 days ago
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others...
Share to Feed
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter PeptiDream) (Tokyo: 4587) today announced an expansion of its peptide...
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...
Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session
US equity futures swung between gains and losses and traded near session highs as US traders...
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
read...
Novartis CEO: Broadly Positive About Business Momentum...
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results...
Novartis Raises Guidance on Profit, Sales Growth...
Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore
Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...
It's been a busy week for Swiss healthcare giant Novartis. In a series of days, the company said it's slowing trials of its blockbuster cancer drug and slashing hundreds of jobs and attempting to...